Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $193,390.74 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $16.47, for a total transaction of $193,390.74. Following the completion of the transaction, the insider now directly owns 159,782 shares of the company's stock, valued at approximately $2,631,609.54. This trade represents a 6.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded up $0.01 during mid-day trading on Friday, hitting $16.92. 799,943 shares of the company were exchanged, compared to its average volume of 533,266. Centessa Pharmaceuticals plc has a 1-year low of $7.38 and a 1-year high of $18.97. The stock has a market capitalization of $2.23 billion, a PE ratio of -11.06 and a beta of 1.53. The business has a 50 day simple moving average of $16.77 and a 200-day simple moving average of $15.13. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP raised its position in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after buying an additional 3,108 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $148,000. Finally, Walleye Capital LLC acquired a new stake in Centessa Pharmaceuticals during the third quarter worth approximately $187,000. Institutional investors own 82.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CNTA shares. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.